Evidence map›Paper›PMID 26963090›Full record

ArticlePloS one2016

A New Application of Parallel Synthesis Strategy for Discovery of Amide-Linked Small Molecules as Potent Chondroprotective Agents in TNF-α-Stimulated Chondrocytes.

Chia-Chung Lee, Yang Lo, Ling-Jun Ho, Jenn-Haung Lai, Shiu-Bii Lien, Leou-Chyr Lin, Chun-Liang Chen, Tsung-Chih Chen, Feng-Cheng Liu, Hsu-Shan Huang

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Synthesis and Spectrum of Biological Activities of Novel N-arylcinnamamides.International journal of molecular sciences · 2018
    Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Chia-Chung LeeGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Yang LoSchool of Pharmacy, National Defense Medical Center, Taipei, Taiwan.
Ling-Jun HoInstitute of Cellular and System Medicine, National Health Research Institute, Zhunan, Taiwan.
Jenn-Haung LaiDivision of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan, Taiwan.
Shiu-Bii LienDepartment of Orthopaedics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Leou-Chyr LinDepartment of Orthopaedics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Chun-Liang ChenGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Tsung-Chih ChenGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Feng-Cheng LiuGraduate Institute of Medical Science, National Defense Medical Center, Taipei, Taiwan.
Hsu-Shan HuangGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
National Defense Medical Center · TWTaipei Medical University · TWTri-Service General Hospital · TWChang Gung University · TWNational Health Research Institutes · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As part of an effort to profile potential therapeutics for the treatment of inflammation-related diseases, a diversity of amide-linked small molecules was synthesized by using parallel synthesis strategy. Moreover, these new compounds were also evaluated for their inhibitory effects on nitric oxide (NO) by using tumor necrosis factor alpha (TNF-α)-induced inflammatory responses in chondrocytes. Among the tested compounds, N-(3-chloro-4-fluorophenyl)-2-hydroxybenzamide (HS-Ck) was the most potent inhibitor of NO production and inducible nitric oxide synthase (iNOS) expression in TNF-α-stimulated chondrocytes. In addition, our biological results indicated that HS-Ck might suppress the expression levels of iNOS and matrix metalloproteinases-13 (MMP-13) activities through downregulating the activation of nuclear factor kappa B (NF-κB) and signal transducer and activator of transcription 3 (STAT-3) transcriptional factors. Therefore, the parallel synthesis was successful used to develop a new class of potential anti-inflammatory agents as chondroprotective candidates for the treatment of osteoarthritis.

Indexed as

AmidesAnimalsBenzamidesCell SurvivalChondrocytesCrystallography, X-RayCytoprotectionHumansMatrix Metalloproteinase 13Models, BiologicalNF-kappa BNitric OxideNitric Oxide Synthase Type IISmall Molecule LibrariesSTAT3 Transcription FactorSus scrofaAmidesBenzamidesMatrix Metalloproteinase 13NF-kappa BNitric OxideNitric Oxide Synthase Type IISmall Molecule LibrariesSTAT3 Transcription FactorTumor Necrosis Factor-alpha

Identifiers

PMID26963090
PMCPMC4786219
OpenAlexW2295182112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.